跳至主要内容
临床试验/NCT02426788
NCT02426788已完成不适用

The PRINCE Secondary Study: Persistent Physical Symptoms Reduction Intervention: a System Change and Evaluation in Secondary Care

King's College London7 个研究点 分布在 1 个国家目标入组 324 人开始时间: 2015年7月最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
324
试验地点
7
主要终点
Work and social adjustment scale

研究概览

简要总结

Brief Summary: Persistent Physical Symptoms (PPS), also known as medically unexplained symptoms (MUS) is a term used to describe a range of persistent bodily symptoms for which the exact cause is unclear. Between 20 and 40% of patients in primary care, and about 50% in secondary care experience PPS. Not only are PPS common, but the overlap across different patient groups may indicate that these phenomena are transdiagnostic. PPS are associated with profound disability and high health care costs, and if left untreated the prognosis of these patients is poor. There is an accumulating body of evidence demonstrating that cognitive behavioural interventions can reduce levels of symptoms and improve functioning in patients with PPS. A pragmatic randomised controlled trial (RCT) was designed to evaluate the clinical and cost-effectiveness of cognitive behavioural therapy (CBT) + Standard Medical Care (SMC) versus Standard Medical Care alone, in the treatment of patients with PPS. The trial will focus on patients with a variety of symptoms (e.g., non-cardiac chest pain, fibromyalgia), across secondary care clinics (e.g., neurology, cardiology, and rheumatology).

详细描述

Background and study aims In primary care between 20 and 40% of patients have medically unexplained physical symptoms. The term medically unexplained symptoms (MUS) is commonly used by health care professionals. However a survey of a healthy population and a separate survey of patients with chronic fatigue syndrome (CFS) suggested that the term persistent physical symptoms (PPS) was the preferred term. The term PPS may have its drawbacks, but it will be used in the rest of this document to cover MUS as well as any other terms that may be used in the literature and clinical settings to refer to these symptoms. In secondary care, about 50% of patients have PPS, in many specialties. PPS are associated with profound disability and high health care costs. Around 50% of sufferers have co-morbid anxiety and depression and sleep problems. Left untreated, the prognosis of these patients is poor.

This study is a pragmatic RCT that will evaluate the clinical and cost-effectiveness of cognitive behavioural therapy + standard medical care (CBT+SMC), which involves 8 sessions of CBT, versus standard medical care (SMC) in the treatment of patients with PPS.

Who can participate? Patients with various PPS, such as fibromyalgia, non-cardiac chest pain, irritable bowel syndrome and a range of neurological symptoms e.g., weakness will be recruited. Participants will be recruited from clinics in secondary care (e.g., neurology, cardiology, rheumatology) at various hospitals in London.

What does the study involve? Potential participants will be identified by clinical staff who will refer them to the research team. Patients who give their consent to take part in the study will complete a number of questionnaires asking about their symptoms and use of health care services, and about their thoughts, feelings, and beliefs related to their PPS (i.e., baseline). This will take approximately 1.5 hours. After this research assessment, half of participants will be randomly assigned to the treatment arm (CBT+SMC), or to the control (SMC) arm. Participants in the treatment arm will receive 8 individual sessions of CBT (weekly or fortnightly sessions). The therapy aims to help the patient develop an understanding of the relationship between cognitive, physiological and behavioural aspects of their problem; to understand factors that may be maintaining the problem and to learn how to modify their behavioural and cognitive responses in order to improve their quality of life. Participants in the SMC group will receive usual medical care within the clinic.

Participants in both arms will also be asked to complete questionnaires at 9, 20, 40, and 52 weeks after randomisation. The assessment will be independent of the health care professionals delivering care.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • Active psychosis;
  • Factitious disorder;
  • Headaches as the only PPS;
  • Non-epileptic seizures
  • Current alcohol dependence or drug addiction as assessed by the clinician;
  • Current benzodiazepine use exceeding the equivalent of 10mg diazepam/day;
  • The patient is currently receiving CBT/CBT based approach psychotherapy, or has received CBT/CBT based approach psychotherapy in the past year, for their PPS;
  • The patient is thought to be at imminent risk of self-harm;
  • Patient is taking part in PRINCE Primary trial.

研究组 & 干预措施

CBT+SMC

Experimental

Cognitive behavioural therapy + Standard Medical Care (cognitive-behavioural therapy+SMC):

8 hour-long manual-based CBT sessions with a therapist, weekly or fortnightly.

干预措施: Cognitive behavioural therapy (CBT) (Behavioral)

Standard Medical Care (SMC)

No Intervention

Participants assigned to the SMC group (i.e., control group) will receive all the treatment and support they would otherwise receive outside of a research trial.

结局指标

主要结局

Work and social adjustment scale

时间窗: 52 weeks post randomisation

Measures impairment in functioning

次要结局

  • Patient Health Questionnaire-9 (PHQ-9)(52 weeks post randomisation)
  • Generalized Anxiety Disorder-7 (GAD-7)(52 weeks post randomisation)
  • Clinical Global Impression (CGI)(52 weeks post randomisation)
  • Cognitive Behavioural Responses Questionnaire(52 weeks post randomisation)
  • Patient Health Questionnaire-15 (PHQ-15)(52 weeks post randomisation)
  • Client Service Receipt Inventory (CSRI)(52 weeks post randomisation)
  • Persistent Physical Symptom Questionnaire(52 weeks post randomisation)
  • EuroQol-5D (EQ-5D)(52 weeks post randomisation)
  • Acceptance scale(52 weeks post randomisation)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (7)

Loading locations...

相似试验

CBT Plus SMC Compared to SMC for Persistent Physical... | 临床试验